Silfarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,540 | 565 | 750 | 271,520 | 289,395 | 355,918 | 335,339 | 331,982 |
| Profit before tax | 1,540 | 565 | 750 | 452 | 932 | 1,060 | 1,000 | -7,706 |
| Net profit | 1,309 | 480 | 638 | 384 | 792 | 901 | 850 | -7,706 |
| Equity | 42,165 | 42,645 | 24,483 | 24,867 | 25,659 | 26,560 | 27,410 | 19,704 |
| Liabilities | 14,581 | 16,841 | 13,896 | 31,209 | 42,226 | 41,326 | 60,605 | 65,402 |
| Non-current assets | 20,643 | 18,215 | 152 | 152 | 152 | 152 | 152 | 7,758 |
| Current assets | 36,103 | 41,271 | 38,227 | 55,924 | 67,733 | 67,734 | 87,863 | 77,348 |
| Total assets | 56,746 | 59,486 | 38,379 | 56,076 | 67,885 | 67,886 | 88,015 | 85,106 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 11,589 | 16,380 | 20,312 |
| Social insurance contributions | - | - | - | - | - | 15,106 | 17,350 | 16,285 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -70.7% | -63.3% | +32.7% | +36102.7% | +6.6% | +23.0% | -5.8% | -1.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 2.3% | 0.8% | 1.7% | 0.7% | 1.2% | 1.3% | 1.0% | -9.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 3.1% | 1.1% | 2.6% | 1.5% | 3.1% | 3.4% | 3.1% | -39.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 85.0% | 85.0% | 85.1% | 0.1% | 0.3% | 0.3% | 0.3% | -2.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 100.0% | 100.0% | 100.0% | 0.2% | 0.3% | 0.3% | 0.3% | -2.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.4 | 0.6 | 1.3 | 1.6 | 1.6 | 2.2 | 3.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 164 | 58 | 84 | 28,581 | 32,455 | 43,142 | 46,791 | 55,330 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Silfarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-25 | 0.01 |
| 2026-05-12 | 2026-05-12 | 0.07 |
| 2026-01-21 | 2026-02-16 | 0.01 |
| 2026-01-01 | 2026-01-13 | 0.80 |
| 2025-12-16 | 2025-12-30 | 0.80 |
| 2024-05-16 | 2024-05-23 | 0.91 |
| 2024-04-23 | 2024-05-14 | 0.92 |
| 2024-01-23 | 2024-02-18 | 0.33 |
| 2024-01-16 | 2024-01-22 | 0.01 |
Silfarma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-07-03 | 2026-07-07 | 42.91 |
| 2026-06-29 | 2026-07-02 | 42.86 |
| 2026-06-05 | 2026-06-05 | 67.4 |
| 2026-05-14 | 2026-05-14 | 67.02 |
| 2026-02-21 | 2026-02-27 | 0.2 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Silfarma, UAB (code 169273422) is a Private Limited Liability Company operating in non-specialised retail sale of predominately food, beverages or tobacco. In 2025, the latest financial year, revenue was €332.0K, down 1.0% year on year and 6.7% below the 2023 level. Profitability weakened materially: net profit turned into a loss of €7.7K in 2025, compared with a profit of €850 in 2024 and €901 in 2023. The 2025 profit margin was -2.3%, after margins of 0.3% in both prior years. Balance sheet size remained modest, with total assets of €85.1K, equity of €19.7K and liabilities of €65.4K at year-end 2025. The equity ratio stood at 23.1%, while debt-to-equity was 3.32. Asset turnover was 3.90x, indicating relatively high sales intensity relative to assets. Revenue per employee was €55.3K, while profit per employee was negative at -€1.3K. Over the three-year period, the company showed gradually declining revenue and a clear deterioration in profitability in 2025.